COVID-19 치료제

Nirmatelvir/ritonavir (Paxlovid)

Nirmatelvir/ritonavir (Paxlovid): 

The only agent authorized for use in Canada

The 1st oral antiviral therapy approved by Health Canada for use in high-risk adults with mild-to-moderate COVID-19

Dosage: 300mg/100mg BID X 5 days

The 5-day treatment course should be initiated as soon as possible after a diagnosis of

 COVID-19 has been made, and within 5 days of symptom onset

Provinces have established their own guidelines on the use of nirmatelvir/ritonavir

Mechanism: Nirmatrelvir→ blocks the SARS-CoV-2 main protease -essential for viral                                                       replication

                                            === inhibits SARS-C0V-2 replication

                     Ritonavir → inhibits CYP 3A4=== when co-administered with nirmatrelvir                                              ===slows nirmatrelvir metabolism by CYP 3A4 ===extents the                                                      bioavailability of nirmatrelvir

        Example of Eligibility and Access to Nirmatrelvir/Ritonavir: British Columbia